Cancer cells often survive treatment by fixing the DNA damage that therapy is meant to cause. Researchers found that UNI418 can disrupt this repair ability, leaving cancer cells more exposed. When combined with a PARP inhibitor, it helped resistant cancer cells respond to treatment again. The findings point to a new strategy for overcoming cancer drug resistance.